Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;27(5):e15182.
doi: 10.1111/1756-185X.15182.

Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases

Russka Shumnalieva  1 , Tsvetelina Velikova  2 , Simeon Monov  1
Affiliations
Review

Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases

Russka Shumnalieva et al. Int J Rheum Dis. 2024 May.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy where the lymphocytes, mostly T-cells, are redirected to specifically recognize and eliminate a target antigen by coupling them with CARs. The binding of CAR and target cell surface antigens leads to vigorous T cell activation and robust anti-tumor immune responses. Areas of implication of CAR T-cell therapies include mainly hematological malignancies (i.e., advanced B-cell cancers); however, recent studies have proven the unprecedented success of the new immunotherapy also in autoimmune rheumatic diseases. We aim to review the recent advances in CAR T-cell therapies in rheumatology but also to address the limitations of their use in the real clinical practice based on the data on their efficacy and safety.

Keywords: CAR T‐cell therapy; cell‐based therapy; chimeric antigen receptor; efficacy; rheumatic diseases; safety.

PubMed Disclaimer

References

REFERENCES

    1. Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545(7655):423‐431. doi:10.1038/nature22395
    1. Xu D, Jin G, Chai D, et al. The development of CAR design for tumor CAR‐T cell therapy. Oncotarget. 2018;9:13991‐14004. doi:10.18632/oncotarget.24179
    1. Bao L, Bo XC, Cao HW, et al. Engineered T cells and their therapeutic applications in autoimmune diseases. Zool Res. 2022;43(2):150‐165. doi:10.24272/j.issn.2095-8137.2021.363
    1. Choi G, Shin G, Bae S. Price and prejudice? The value of chimeric antigen receptor (CAR) T‐cell therapy. Int J Environ Res Public Health. 2022;19(19):12366. doi:10.3390/ijerph191912366
    1. Gajra A, Zalenski A, Sannareddy A, Jeune‐Smith Y, Kapinos K, Kansagra A. Barriers to chimeric antigen receptor T‐cell (CAR‐T) therapies in clinical practice. Pharmaceut Med. 2022;36(3):163‐171. doi:10.1007/s40290-022-00428-w

MeSH terms

LinkOut - more resources